Kay Hagan Tick Reauthorization Act

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The primary purpose of S. 2398 is to extend the authorization of federal programs targeting tick-borne and other vector-borne diseases through fiscal year 2030. This reauthorization ensures continued funding and structural support for surveillance, research, and public health coordination aimed at mitigating the spread of diseases such as Lyme disease, Rocky Mountain spotted fever, and emerging threats like babesiosis and Powassan virus. The bill’s nominal objective is to strengthen national preparedness and response capacity, though its real function lies in maintaining a predictable flow of federal resources into a niche public health sector with growing epidemiological relevance due to climate-driven habitat expansion of tick populations.

**2. Key Provisions & Changes to Existing Law** The bill amends two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases)**: - Replaces the mandatory inclusion of the Tick-Borne Disease Working Group (established under the 21st Century Cures Act) with a more flexible directive to consult “appropriate individuals,” thereby reducing bureaucratic rigidity and increasing administrative discretion. - Changes the coordination language from “in coordination with” to “acting through,” centralizing authority and streamlining decision-making—an efficiency gain from a technocratic standpoint. - Extends the authorization period for funding and program activities from 2021–2025 to 2026–2030, ensuring a five-year extension of federal support. - **Section 2822(c) (Enhanced Support to Assist Health Departments)**: - Similarly extends the authorization period for grants and technical assistance to state, local, and tribal health departments from 2021–2025 to 2026–2030, sustaining financial and operational support for frontline vector-borne disease monitoring and response.

**3. Affected Parties & Stakeholders** - **Federal Agencies**: The CDC and HHS gain extended mandate and funding stability, reducing the need for recurrent appropriations battles. - **State and Local Health Departments**: Continue to receive federal grants and technical assistance, maintaining capacity for surveillance, diagnostics, and public outreach. - **Academic and Research Institutions**: Benefit from sustained funding for Regional Centers of Excellence, enabling long-term studies on pathogen ecology, diagnostics, and vaccines. - **Private Sector**: Diagnostic firms, vaccine developers, and vector control companies may see continued demand for innovations in this space, though the bill does not directly subsidize private enterprise. - **General Public**: Indirect beneficiaries through reduced disease incidence, though the bill offers no direct consumer-facing protections or mandates.

**4. Potential Impact & Implications** From a wealth and power perspective, this bill represents a low-cost, high-reliability investment in public health infrastructure that minimizes systemic risk without disrupting market dynamics. By extending existing programs rather than creating new mandates, it avoids regulatory overreach while ensuring that critical surveillance networks remain operational—a prerequisite for early detection of outbreaks that could otherwise disrupt labor markets, travel, or regional economies. The streamlining of interagency coordination (“acting through”) enhances operational efficiency, aligning with a technocratic preference for lean, expert-driven governance over democratic deliberation.

While the bill does not generate direct profit, it protects and potentially expands the operational environment for biotech and public health contracting firms in which sophisticated investors may hold interests. More importantly, it prevents the erosion of federal capacity in a domain where underinvestment could lead to costly emergent crises. In essence, S. 2398 is a defensive, rational allocation of state capacity—one that preserves elite interests by averting avoidable public health disruptions, all while avoiding the inefficiencies of expansive regulation or populist overreach. It is governance as risk management: quiet, precise, and utterly indifferent to electoral theater.

Main Purpose & Objectives The Kay Hagan Tick Reauthorization Act (S. 2398) seeks to extend and update federal efforts to combat tick-borne diseases by reauthorizing two key programs under the Public Health Service Act. As I taught you in 8th grade civics—*remember when we learned how Congress updates existing laws through amendments?*—this bill doesn’t create new programs from scratch but modifies and extends the duration of existing ones. Its primary objective is simple: continue funding and coordination for vector-borne disease prevention, surveillance, and response through 2030, replacing the prior expiration date of 2025. The bill honors Senator Kay Hagan’s advocacy on Lyme disease and related illnesses, ensuring her initiative doesn’t lapse due to congressional inaction—a basic function of legislative oversight we covered when discussing how laws evolve over time.

Key Provisions & Changes to Existing Law The bill makes three specific, technical amendments: First, it updates Section 317U of the Public Health Service Act (42 U.S.C. 247b-23), which governs the National Strategy and Regional Centers of Excellence in Vector-borne Diseases. It removes a reference to the Tick-Borne Disease Working Group (established under the 21st Century Cures Act) as a mandatory coordinator, replacing it with broader language allowing coordination through “appropriate individuals.” It also changes the procedural phrasing from “in coordination with” to “acting through”—a subtle but meaningful shift in administrative authority. Most significantly, it extends the authorization period from 2021–2025 to 2026–2030. Second, it amends Section 2822(c) (42 U.S.C. 300hh-32(c)), which provides enhanced support to state and local health departments for vector-borne disease efforts, applying the same timeline extension (2026–2030). These are not sweeping reforms—they’re housekeeping measures, the kind of routine reauthorizations that should fly through Congress without drama, assuming legislators actually read the bills they vote on, unlike some who seem to have skipped the unit on how federal health programs get renewed.

Affected Parties & Stakeholders This bill directly impacts: - Federal agencies (CDC, NIH) overseeing vector-borne disease strategy - Regional Centers of Excellence (academic and research institutions) - State and local public health departments receiving grants for surveillance, diagnostics, and prevention - Patients and advocacy groups concerned with Lyme disease, Rocky Mountain spotted fever, and other tick-borne illnesses - Researchers studying ecological and clinical aspects of vector-borne pathogens The stakeholders here aren’t partisan—they’re epidemiologists, clinicians, and public health workers who’ve been waiting for this reauthorization to avoid funding gaps. If you’d paid attention in our lesson on how public health policy actually gets made, you’d know these extensions prevent disruptive lapses in critical disease monitoring.

Potential Impact & Implications By extending authorization through 2030, the bill ensures continuity in federal coordination, research funding, and grassroots support for tick-borne disease mitigation. Without this reauthorization, programs could face uncertainty, disrupted grant cycles, or reduced interagency collaboration—precisely the kind of avoidable dysfunction we discussed when learning about why timely legislative action matters. The changes to coordination language may streamline decision-making, though removing explicit mention of the Tick-Borne Disease Working Group raises questions about whether specialized expertise will be adequately consulted. Overall, the impact is preventive: maintaining the status quo of a functioning, if under-resourced, national response system. It’s not exciting, but as I repeatedly explained in civics class, *good governance often looks like boring, necessary maintenance*—not crisis management. If Congress can’t handle this, what hope do we have for the hard stuff?

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The primary purpose of S. 2398, the Kay Hagan Tick Reauthorization Act, is to extend and update federal efforts to combat tick-borne diseases by reauthorizing key provisions of the original Kay Hagan Tick Act. Named in honor of the late Senator Kay Hagan, who died from complications of Powassan virus—a tick-borne illness—the bill aims to strengthen national preparedness, improve coordination among federal and state health agencies, and enhance research, surveillance, and public health responses to vector-borne diseases, particularly those transmitted by ticks. The overarching objective is to extend critical public health infrastructure through 2030 to address the growing threat of Lyme disease and other tick-borne illnesses, which have seen rising incidence due to climate change and expanding tick habitats.

**2. Key Provisions & Changes to Existing Law** The bill makes targeted amendments to two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases):** - Replaces the mandatory inclusion of the *Tick-Borne Disease Working Group* (established under the 21st Century Cures Act) with a more flexible requirement to consult “appropriate individuals,” broadening potential advisory input. - Changes the phrasing from “in coordination with” to “acting through” in subsection (c), suggesting a shift toward more centralized federal implementation rather than collaborative partnership. - Extends the authorization period for funding and operations from 2021–2025 to **2026–2030**, ensuring continuity of programs. - **Section 2822(c) (Enhanced Support to Assist Health Departments):** - Similarly extends the timeframe for federal support to state and local health departments in addressing vector-borne diseases from 2021–2025 to **2026–2030**, maintaining grants, technical assistance, and capacity-building efforts.

**3. Affected Parties & Stakeholders** - **Federal Agencies:** CDC, NIH, and HHS will oversee implementation, particularly through the National Strategy and Regional Centers of Excellence. - **State and Local Health Departments:** Primary recipients of enhanced support for surveillance, diagnostics, and public education. - **Research Institutions & Universities:** Likely beneficiaries of continued funding for tick-borne disease research via Regional Centers of Excellence. - **Patients and Advocacy Groups:** Individuals affected by Lyme disease, babesiosis, anaplasmosis, Powassan virus, and other tick-borne illnesses stand to gain from improved diagnostics and treatment research. - **The Public:** Increased awareness and prevention efforts may reduce infection rates over time.

**4. Potential Impact & Implications** By reauthorizing these programs through 2030, the bill ensures sustained federal investment in a public health challenge that has historically been underfunded relative to its burden. The shift from “in coordination with” to “acting through” may raise concerns among state and local partners about reduced autonomy, though it could also streamline response efforts. Removing the explicit mandate to include the Tick-Borne Disease Working Group could weaken patient advocacy representation in advisory processes, though the bill retains flexibility for inclusive engagement. Overall, the act reinforces a long-term federal commitment to vector-borne disease preparedness, aligning with broader climate-adaptive health strategies. If effectively implemented, it could lead to better surveillance, faster outbreak responses, and improved patient outcomes—though success will depend on adequate appropriations and interagency collaboration.

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The Kay Hagan Tick Reauthorization Act (S. 2398) seeks to extend and modestly refine federal efforts to combat tick-borne diseases by reauthorizing two key public health programs through 2030. Named in honor of the late Senator Kay Hagan, who died from complications of Powassan virus—a tick-borne illness—the bill aims to sustain surveillance, research, and coordination on vector-borne diseases like Lyme disease, anaplasmosis, and babesiosis. Its stated objective is to protect American families from the growing threat of tick-borne illnesses, which public health officials warn are spreading due to climate change and suburban encroachment on wooded areas. The bill frames this as a matter of national health security and individual freedom—freedom, of course, to enjoy the outdoors without fear of debilitating illness brought to you by the same elites who ignore rural America until election season.

**2. Key Provisions & Changes to Existing Law** S. 2398 amends two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases):** - Replaces language requiring coordination with the Tick-Borne Disease Working Group (established under the 21st Century Cures Act) with a broader mandate to work with “appropriate individuals,” streamlining advisory input. - Changes “in coordination with” to “acting through” in subsection (c), subtly shifting accountability from collaborative partnership to direct federal execution. - Extends the authorization period from 2021–2025 to **2026–2030**, ensuring five more years of funding and program operation. - **Section 2822(c) (Enhanced Support to Assist Health Departments):** - Similarly extends the timeframe from 2021–2025 to **2026–2030** for grants and technical support to state, local, and tribal health departments in detecting, preventing, and responding to vector-borne diseases.

These are largely technical, housekeeping amendments—no new funding levels are specified, and no major structural overhauls are proposed. The bill essentially puts the existing tick-borne disease infrastructure on autopilot for another half-decade.

**3. Affected Parties & Stakeholders** - **Federal Agencies:** The CDC and HHS will continue administering the programs, with slightly altered interagency coordination expectations. - **State, Local, and Tribal Health Departments:** Remain eligible for grants and technical assistance to bolster tick surveillance, public education, and rapid response capacity. - **Researchers and Academic Institutions:** Regional Centers of Excellence will continue receiving support for studies on diagnostics, vaccines, and ecological controls. - **Patients and Advocacy Groups:** Organizations like the Lyme Disease Association and patient advocates benefit from sustained federal attention, though the bill does not address long-haul symptoms or treatment controversies. - **The General Public:** Outdoor enthusiasts, pet owners, and rural residents gain indirect benefit from continued prevention efforts—though one might wonder why it takes a senator’s tragic death to renew focus on a crisis affecting thousands annually.

**4. Potential Impact & Implications** The bill’s impact is largely one of continuity. By extending existing authorities without significant reform, S. 2398 maintains the status quo in federal tick-borne disease policy. While this prevents a lapse in critical surveillance and response capabilities, it also misses an opportunity to address persistent gaps: underfunded diagnostics, inconsistent state reporting, limited access to care for chronic symptoms, and the lack of a licensed human Lyme vaccine.

Politically, the bill is low-risk and high-symbolism—a bipartisan tribute that lets lawmakers claim action on public health without confronting controversial topics like climate change’s role in disease spread or the influence of agricultural and real estate lobbies on land-use policies that increase human-tick contact.

In true Washington fashion, S. 2398 reauthorizes a well-intention

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The Kay Hagan Tick Reauthorization Act (S. 2398) seeks to extend and update federal efforts to combat tick-borne and other vector-borne diseases by reauthorizing key programs under the Public Health Service Act. Named in honor of the late Senator Kay Hagan, who died from complications of Powassan virus—a tick-borne illness—the bill aims to strengthen national preparedness, improve coordination among federal and state health agencies, and enhance support for local public health departments in addressing the growing threat of diseases such as Lyme disease, Rocky Mountain spotted fever, and emerging tick-borne pathogens.

**2. Key Provisions & Changes to Existing Law** The bill amends two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases):** - Revises subsection (b) to replace the specific reference to the *Tick-Borne Disease Working Group* (established under the 21st Century Cures Act) with the broader term *“appropriate individuals,”* allowing for more flexible advisory input in developing the national strategy. - Amends subsection (c) to change the coordination language from *“in coordination with”* to *“acting through,”* clarifying the operational relationship between the Centers for Disease Control and Prevention (CDC) and regional centers. - Updates subsection (f) to extend the authorization period for grants and activities from *“2021 through 2025”* to *“2026 through 2030,”* ensuring continued funding for research, surveillance, and prevention initiatives. - **Section 2822(c) (Enhanced Support to Assist Health Departments):** - Similarly extends the authorization period for federal support to state, local, tribal, and territorial health departments in addressing vector-borne diseases from *“2021 through 2025”* to *“2026 through 2030.”* This support includes funding, technical assistance, and capacity-building for disease detection, reporting, and response.

**3. Affected Parties & Stakeholders** - **Federal Agencies:** The CDC and other HHS components will oversee implementation of the national strategy and manage grants to regional centers. - **State, Local, Tribal, and Territorial Health Departments:** Will receive continued federal support to strengthen surveillance, diagnostics, and public education efforts. - **Academic and Research Institutions:** Regional Centers of Excellence, often based at universities, will benefit from extended grant opportunities to conduct research on vector-borne diseases. - **Healthcare Providers:** May see improved access to updated guidance, diagnostic tools, and training on emerging tick-borne illnesses. - **General Public:** Particularly those in endemic regions (e.g., Northeast, Upper Midwest, and Pacific Coast), will benefit from enhanced prevention efforts and earlier detection of diseases. - **Advocacy Groups:** Organizations focused on Lyme disease and other tick-borne illnesses (e.g., Lyme Disease Association, Tick-Borne Disease Alliance) are likely to support the bill’s focus on sustained federal engagement.

**4. Potential Impact & Implications** By reauthorizing these programs through 2030, the bill ensures continuity in federal efforts to address a growing public health challenge. Climate change and expanding tick habitats have contributed to rising incidence of vector-borne diseases across the U.S., making sustained investment in surveillance, research, and local capacity critical. The shift from mandating coordination with the Tick-Borne Disease Working Group to consulting “appropriate individuals” may streamline advisory processes but could reduce transparency if not implemented with inclusive stakeholder engagement. Overall, the bill supports a more resilient public health infrastructure capable of responding to both established and emerging threats, potentially reducing long-term healthcare costs and improving outcomes for affected individuals. Its passage reflects ongoing bipartisan recognition of vector-borne diseases as a significant national health priority.

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The Kay Hagan Tick Reauthorization Act (S. 2398) aims to extend and refine federal efforts to combat tick-borne and other vector-borne diseases by reauthorizing key programs under the Public Health Service Act. Named in honor of the late Senator Kay Hagan, who advocated for Lyme disease awareness after her personal experience, the bill seeks to strengthen national preparedness, improve coordination among health agencies, and enhance support for state and local health departments in addressing the growing threat of diseases like Lyme, Rocky Mountain spotted fever, and others transmitted by ticks and mosquitoes.

**2. Key Provisions & Changes to Existing Law** The bill makes targeted amendments to two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases):** - Removes the specific reference to the *Tick-Borne Disease Working Group* (established under the 21st Century Cures Act) as a required participant in developing the national strategy, replacing it with broader language calling for “appropriate individuals.” This allows for more flexible inclusion of experts beyond the Working Group. - Changes the phrasing from “in coordination with” to “acting through” regarding how the Centers for Disease Control and Prevention (CDC) implements the program, potentially streamlining federal oversight. - Extends the authorization period for funding and program activities from **2021 through 2025** to **2026 through 2030**, ensuring continuity of efforts. - **Section 2822(c) (Enhanced Support to Assist Health Departments):** - Similarly extends the authorization timeline from **2021 through 2025** to **2026 through 2030**, maintaining federal grants and technical assistance to state, local, and tribal health departments for surveillance, prevention, and response to vector-borne diseases.

**3. Affected Parties & Stakeholders** - **Federal Agencies:** Primarily the CDC and HHS, responsible for implementing the national strategy and distributing funds. - **State, Local, and Tribal Health Departments:** Core recipients of enhanced support for disease tracking, public education, and outbreak response. - **Research Institutions & Academic Centers:** Likely beneficiaries as Regional Centers of Excellence, which conduct research and train public health professionals. - **Healthcare Providers:** Indirectly benefit through improved diagnostics, treatment guidelines, and disease reporting systems. - **Patients & Advocacy Groups:** Especially those affected by Lyme disease and other tick-borne illnesses, who stand to gain from better surveillance and prevention efforts. - **The Public:** Faces reduced risk of vector-borne diseases through improved prevention and early detection.

**4. Potential Impact & Implications** By reauthorizing these programs through 2030, the bill ensures sustained federal investment in a public health challenge that has grown due to climate change, expanding tick habitats, and increased outdoor recreation. The shift from mandatory inclusion of the Tick-Borne Disease Working Group to “appropriate individuals” may allow for more agile, science-driven strategy updates, though some advocates may worry about reduced patient representation. The extension of funding timelines provides stability for long-term research and infrastructure projects at the state and local levels. Overall, the bill represents a pragmatic, non-controversial renewal of existing public health infrastructure—less about sweeping reform and more about maintaining momentum in the fight against diseases that affect hundreds of thousands of Americans annually. Its quiet passage reflects broad bipartisan recognition that vector-borne threats are a persistent, growing concern requiring ongoing federal attention.

**Summary of S. 2398: Kay Hagan Tick Reauthorization Act**

**1. Main Purpose & Objectives** The Kay Hagan Tick Reauthorization Act seeks to extend and modestly update the Kay Hagan Tick Act, originally enacted as part of the 21st Century Cures Act to combat the rising threat of tick-borne diseases such as Lyme disease. The bill’s primary objective is to reauthorize federal programs focused on surveillance, research, prevention, and treatment of vector-borne diseases through 2030, ensuring continued coordination between federal agencies, state health departments, and academic research centers.

**2. Key Provisions & Changes to Existing Law** The bill amends two sections of the Public Health Service Act: - **Section 317U (National Strategy and Regional Centers of Excellence in Vector-borne Diseases):** - Removes the specific mandate to coordinate with the Tick-Borne Disease Working Group (established under the 21st Century Cures Act), replacing it with broader language requiring coordination with “appropriate individuals.” This change streamlines interagency collaboration but may reduce formal oversight from the expert working group. - Replaces “in coordination with” with “acting through” in subsection (c), shifting the operational relationship between CDC and regional centers to a more direct, hierarchical model. - Extends the authorization period for funding from 2021–2025 to **2026–2030**, ensuring five additional years of federal support for regional centers of excellence and national strategy development. - **Section 2822(c) (Enhanced Support to Assist Health Departments):** - Similarly extends the authorization period for grants to state, local, and tribal health departments from 2021–2025 to **2026–2030**, sustaining financial and technical assistance for local vector-borne disease surveillance, reporting, and response capacity.

**3. Affected Parties & Stakeholders** - **Federal Agencies:** CDC (primary administrator), NIH, and HHS will oversee implementation of the national strategy and grant distribution. - **State, Local, and Tribal Health Departments:** Core recipients of enhanced support grants for surveillance, workforce training, and public education. - **Academic and Research Institutions:** Regional Centers of Excellence (e.g., at universities in endemic regions) will continue receiving funding for research, diagnostics, and workforce development. - **Patients and Advocacy Groups:** Organizations like the Lyme Disease Association and patients affected by tick-borne illnesses benefit from sustained research and improved public health infrastructure. - **Healthcare Providers:** Gain access to updated guidance, diagnostic tools, and reporting systems supported by the program.

**4. Potential Impact & Implications** The reauthorization ensures continuity of critical public health infrastructure amid expanding tick habitats due to climate change and increasing Lyme disease incidence (CDC estimates ~476,000 annual U.S. cases). By extending funding through 2030, the bill supports long-term research into vaccines, improved diagnostics, and provider education. The removal of explicit reference to the Tick-Borne Disease Working Group may raise concerns among patient advocates about diminished expert input, though the bill retains flexibility for interagency coordination. Overall, the act strengthens national preparedness without introducing new mandates or significant funding increases—essentially a renewal of existing, widely supported efforts. No major industry conflicts or donor-driven provisions are evident; the bill appears driven by public health necessity rather than special interest influence.